Arena Pharmaceuticals Inc.’s obesity drug disappointed investors in a second big clinical trial, sending shares plunging 33 percent on Friday from their highs on Thursday night.
*For more on this story,
read the full Reuters
article.
Arena Pharmaceuticals Inc.’s obesity drug disappointed investors in a second big clinical trial, sending shares plunging 33 percent on Friday from their highs on Thursday night.
*For more on this story,
read the full Reuters
article.
Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!
One-Year for Only $99